Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Read More…
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone858-202-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.33 billion
Profitability
Miscellaneous
Employees7,300
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable
Illumina (NASDAQ:ILMN) Frequently Asked Questions
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Monday, July, 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.03. The life sciences company earned $838 million during the quarter, compared to analysts' expectations of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The firm's revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.43 earnings per share. View Illumina's Earnings History.
When is Illumina's next earnings date?
How can I listen to Illumina's earnings call?
Illumina will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Illumina issued on next quarter's earnings?
Illumina updated its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $6.00 to $6.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.38. The company issued revenue guidance of ~6% (~$3.53 billion), compared to the consensus revenue estimate of $3.62 billion.
What price target have analysts set for ILMN?
13 analysts have issued 12 month target prices for Illumina's shares. Their predictions range from $280.00 to $370.00. On average, they expect Illumina's stock price to reach $328.73 in the next twelve months. This suggests a possible upside of 6.1% from the stock's current price. View Analyst Price Targets for Illumina.
What is the consensus analysts' recommendation for Illumina?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.
What are Wall Street analysts saying about Illumina stock?
Here are some recent quotes from research analysts about Illumina stock:
- 1. Canaccord Genuity analysts commented, "We don’t believe an ultra-premium multiple is now justified for a company looking to grow +6% on the top and bottom lines, which now seem more vulnerable to large misses. What’s more, we lack visibility to 2020 or 2021 growth rates given a wide range of moving parts. We would look to get more constructive if our concerns prove to be transitory, or if ILMN announces the $100 genome at a price point that would meaningfully accelerate its top line and not add further headwinds to its gross, operating or net income margins. ILMN is working hard to drive down the cost of sequencing to be able to usher in the eagerly awaited $100 genome. DTC troubles. On the call, Illumina CEO Francis deSouza indicated he expects a DTC reacceleration “in the coming years,” which to us doesn’t imply a recovery in 2020." (7/30/2019)
- 2. According to Zacks Investment Research, "Illumina continues to register strong top line growth across the company’s high throughput, mid throughput and low throughput categories. In the last-reported fourth quarter, the company observed strong demand for sequencing and array systems, consumables and services. Meanwhile HiSeq to NovaSeq upgrade cycle is progressing well and NextSeq placements are strong. We are also looking forward to the company's newly-inked Pacific Biosciences deal. In the past year, Illumina has outperformed its industry. However, we note that, Illumina exited the fourth quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate. HiSeq consumables are continuing with their expected decline. Seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company is operating in a tough competitive landscape." (4/2/2019)
Has Illumina been receiving favorable news coverage?
News headlines about ILMN stock have trended positive on Wednesday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Illumina earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave press coverage about the life sciences company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Illumina.
Are investors shorting Illumina?
Illumina saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 3,350,000 shares, an increase of 20.5% from the August 30th total of 2,780,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the short-interest ratio is presently 2.7 days. Approximately 2.3% of the company's stock are sold short. View Illumina's Current Options Chain.
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), PerkinElmer (PKI), Avantor (AVTR), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Eyepoint Pharmaceuticals (EYPT).
What other stocks do shareholders of Illumina own?
Who are Illumina's key executives?
Illumina's management team includes the folowing people:
- Mr. Jay T. Flatley, Exec. Chairman (Age 66)
- Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
- Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
- Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
- Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)
Who are Illumina's major shareholders?
Illumina's stock is owned by many different of institutional and retail investors. Top institutional investors include Douglas Lane & Associates LLC (0.25%), Peregrine Capital Management LLC (0.06%), Gateway Investment Advisers LLC (0.05%), Bender Robert & Associates (0.03%), Copper Rock Capital Partners LLC (0.03%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Robert P Ragusa and Robert S Epstein. View Institutional Ownership Trends for Illumina.
Which major investors are selling Illumina stock?
ILMN stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, CIBC Private Wealth Group LLC, HMS Capital Management LLC, Douglas Lane & Associates LLC, Wealthfront Advisers LLC, Crossmark Global Holdings Inc., Private Asset Management Inc. and Evanson Asset Management LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Robert P Ragusa and Robert S Epstein. View Insider Buying and Selling for Illumina.
Which major investors are buying Illumina stock?
ILMN stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Peregrine Capital Management LLC, Quattro Financial Advisors LLC, State of Alaska Department of Revenue, Foster Victor Wealth Advisors LLC, Pacer Advisors Inc., DNB Asset Management AS and Diversified Trust Co. View Insider Buying and Selling for Illumina.
How do I buy shares of Illumina?
Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Illumina's stock price today?
One share of ILMN stock can currently be purchased for approximately $309.93.
How big of a company is Illumina?
Illumina has a market capitalization of $45.56 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina.
What is Illumina's official website?
How can I contact Illumina?
Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]
MarketBeat Community Rating for Illumina (NASDAQ ILMN)
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
